Hypofractionated radiotherapy for prostate cancer in the postoperative setting: What is the evidence so far?

Cristina Picardi; Ioan Perret; Raymond Miralbell; Thomas Zilli

doi:10.1016/j.ctrv.2017.11.004

journal article Jan 01, 2018

Hypofractionated radiotherapy for prostate cancer in the postoperative setting: What is the evidence so far?

Cristina Picardi Ioan Perret Raymond Miralbell Thomas Zilli

Cancer Treatment Reviews Vol. 62 pp. 91-96 · Elsevier BV

View at Publisher Save 10.1016/j.ctrv.2017.11.004

Topics

No keywords indexed for this article. Browse by subject →

References

43

[1]

Catalona "Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results" J Urol (1998) 10.1016/s0022-5347(01)62204-3

[2]

Han "Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience" Urol Clin North Am (2001) 10.1016/s0094-0143(05)70163-4

[3]

Roehl "Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results" J Urol (2004) 10.1097/01.ju.0000134888.22332.bb

[4]

Bolla "Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)" Lancet (2012) 10.1016/s0140-6736(12)61253-7

[5]

Trock "Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy" JAMA (2008) 10.1001/jama.299.23.2760

[6]

Fowler "Is the α/β ratio for prostate tumours really low and does it vary with the level of risk at diagnosis?" Anticancer Res (2013)

[7]

Meta-analysis of the Alpha/Beta Ratio for Prostate Cancer in the Presence of an Overall Time Factor: Bad News, Good News, or No News?

Ivan R. Vogelius, Søren M. Bentzen

International Journal of Radiation Oncology*Biolog... 2013 10.1016/j.ijrobp.2012.03.004

[8]

Miralbell "Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy" Int J Radiat Oncol Biol Phys (2012) 10.1016/j.ijrobp.2010.10.075

[9]

Ritter "Hypofractionation for prostate cancer" Cancer J (2009) 10.1097/ppo.0b013e3181976614

[10]

Lee "Prostate cancer and the hypofractionation hypothesis" J Clin Oncol: official journal of the American Society of Clinical Oncology (2013) 10.1200/jco.2013.52.4942

[11]

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

David Dearnaley, Isabel Syndikus, Helen Mossop et al.

The Lancet Oncology 2016 10.1016/s1470-2045(16)30102-4

[12]

Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial

Luca Incrocci, Ruud C Wortel, Wendimagegn Ghidey Alemayehu et al.

The Lancet Oncology 2016 10.1016/s1470-2045(16)30070-5

[13]

Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer

W. Robert Lee, James J. Dignam, Mahul B. Amin et al.

Journal of Clinical Oncology 2016 10.1200/jco.2016.67.0448

[14]

Arcangeli "Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a Phase III randomized trial" J Clin Oncol: official journal of the American Society of Clinical Oncology (2017) 10.1200/jco.2016.70.4189

[15]

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

D. Moher, A. Liberati, J. Tetzlaff et al.

BMJ 2009 10.1136/bmj.b2535

[16]

Lee "Hypofractionated radiotherapy as salvage for rising prostate-specific antigen after radical prostatectomy" Clin Oncol (2004) 10.1016/j.clon.2004.07.006

[17]

Cozzarini "Higher-than-expected severe (Grade 3–4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients" Eur Urol (2014) 10.1016/j.eururo.2014.06.012

[18]

Syndikus "Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control" J Urol (1996) 10.1016/s0022-5347(01)66069-5

[19]

Ippolito "Postoperative intensity-modulated radiotherapy with simultaneous integrated boost in prostate cancer: a dose-escalation trial" Urol Oncol (2013) 10.1016/j.urolonc.2010.10.005

[20]

Kruser "Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence" Cancer (2011) 10.1002/cncr.25824

[21]

Wong "Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy" Int J Radiat Oncol Biol Phys (2008) 10.1016/j.ijrobp.2007.06.042

[22]

Gladwish "Accelerated hypofractioned postoperative radiotherapy for prostate cancer: a prospective phase I/II study" Clin Oncol (2015) 10.1016/j.clon.2014.12.003

[23]

Katayama "Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS-1 trial" Int J Radiat Oncol Biol Phys (2014) 10.1016/j.ijrobp.2014.07.015

[24]

Lewis "Image guided hypofractionated postprostatectomy intensity modulated radiation therapy for prostate cancer" Int J Radiat Oncol Biol Phys (2016) 10.1016/j.ijrobp.2015.11.025

[25]

Fersino "Moderate hypofractionated postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): a mono-institutional report on feasibility and acute toxicity" Clin Genitourin Cancer (2017) 10.1016/j.clgc.2017.01.025

[26]

Koukourakis "Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer" Anticancer Res (2012)

[27]

Cozzarini "Hypofractionated adjuvant radiotherapy with helical tomotherapy after radical prostatectomy: planning data and toxicity results of a Phase I-II study" Radiother Oncol: journal of the European Society for Therapeutic Radiology and Oncology. (2008) 10.1016/j.radonc.2008.03.021

[28]

Fersino "Moderate hypofractionated postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): a mono-institutional report on feasibility and acute toxicity" Clin Genitourin Cancer (2017) 10.1016/j.clgc.2017.01.025

[29]

Massaccesi "Hypofractionated intensity-modulated radiotherapy with simultaneous integrated boost after radical prostatectomy: preliminary results of a phase II trial" Anticancer Res (2013)

[30]

Alongi "Hypofractionation with VMAT versus 3DCRT in post-operative patients with prostate cancer" Anticancer Res (2013)

[31]

Fiorino "Modelling the impact of fractionation on late urinary toxicity after postprostatectomy radiation therapy" Int J Radiat Oncol Biol Phys (2014) 10.1016/j.ijrobp.2014.08.347

[32]

Bentzen "Fractionation sensitivity and latency of late radiation injury to the mouse urinary bladder" Radiother Oncol: journal of the European Society for Therapeutic Radiology and Oncology (1992) 10.1016/0167-8140(92)90251-o

[33]

Jaal "Radiation induced late damage to the barrier function of small blood vessels in mouse bladder" J Urol (2006) 10.1016/j.juro.2006.07.138

[34]

Stewart "Mechanism of bladder damage and repair after treatment with radiation and cytostatic drugs" British J Cancer Supplement (1986)

[35]

Michalski "Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial" Int J Radiat Oncol Biol Phys (2013) 10.1016/j.ijrobp.2013.07.041

[36]

Zilli "Results of dose-adapted salvage radiotherapy after radical prostatectomy based on an endorectal mri target definition model" Am J Clin Oncol (2017) 10.1097/coc.0000000000000130

[37]

Zilli "Dose-adapted salvage radiotherapy after radical prostatectomy based on an erMRI target definition model: toxicity analysis" Acta Oncol (2014) 10.3109/0284186x.2013.837584

[38]

Fortin "Using fiducial markers in the prostate bed in postprostatectomy external beam radiation therapy improves accuracy over surgical clips" Strahlenther Onkol (2014) 10.1007/s00066-014-0631-3

[39]

Kably "Single-center experience in prostate fiducial marker placement: technique and midterm follow-up" J Vasc Interv Radiol (2014) 10.1016/j.jvir.2014.03.017

[40]

Langenhuijsen "Postprostatectomy ultrasound-guided transrectal implantation of gold markers for external beam radiotherapy. Technique and complications rate" Strahlenther Onkol (2013) 10.1007/s00066-013-0323-4

[41]

Shakir "Transrectal implantation and stability of gold markers in prostate bed for salvage radiotherapy of macroscopic recurrences" Phys Med (2016) 10.1016/j.ejmp.2016.10.009

[42]

Zhu "Adaptive radiation therapy for postprostatectomy patients using real-time electromagnetic target motion tracking during external beam radiation therapy" Int J Radiat Oncol Biol Phys (2013) 10.1016/j.ijrobp.2012.08.001

[43]

Krause "Hypofractionated helical intensity-modulated radiotherapy of the prostate bed after prostatectomy with or without the pelvic lymph nodes – the PRIAMOS trial" BMC Cancer (2012) 10.1186/1471-2407-12-504

Cited By

31

Post-operative hypofractionated radiotherapy for prostate cancer: a mono-institutional analysis of toxicity and clinical outcomes

Giuseppe Ferrera, Salvatore D’Alessandro · 2021

Journal of Cancer Research and Clin...

Ten-Year Outcomes of Moderately Hypofractionated Salvage Postprostatectomy Radiation Therapy and External Validation of a Contemporary Multivariable Nomogram for Biochemical Failure

Stephen Chin, Abiola Fatimilehin · 2020

International Journal of Radiation...

Metrics

31

Citations

43

References

Details

Published: Jan 01, 2018
Vol/Issue: 62
Pages: 91-96
License: View

Authors

Cite This Article

Cristina Picardi, Ioan Perret, Raymond Miralbell, et al. (2018). Hypofractionated radiotherapy for prostate cancer in the postoperative setting: What is the evidence so far?. Cancer Treatment Reviews, 62, 91-96. https://doi.org/10.1016/j.ctrv.2017.11.004

Hypofractionated radiotherapy for prostate cancer in the postoperative setting: What is the evidence so far?

You May Also Like